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Objectives: To systematically review the efficacy of
collaborative care (CC) for depression in adults with
coronary heart disease (CHD) and depression.
Design: Systematic review and meta-analysis.
Data sources: Electronic databases (Cochrane Central
Register of Controlled Trials MEDLINE, EMBASE,
PsycINFO and CINAHL) were searched until April
2014.
Inclusion criteria: Population, depression comorbid
with CHD; intervention, randomised controlled trial
(RCT) of CC; comparison, either usual care, wait-list
control group or no further treatment; and outcome,
(primary) major adverse cardiac events (MACE),
(secondary) standardised measure of depression,
anxiety, quality of life (QOL) and cost-effectiveness.
Data extraction and analysis: RevMan V.5.3 was
used to synthesise the data as risk ratios (RRs), ORs
and standardised mean differences (SMD) with 95%
CIs in random effect models.
Results: Six RCTs met the inclusion criteria and
comprised 655 participants randomised to CC and 629
participants randomised to the control group (total
1284). Collaborative depression care led to a
significant reduction in MACE in the short term (three
trials, RR 0.54; 95% CI 0.31 to 0.95, p=0.03) that was
not sustained in the longer term. Small reductions in
depressive symptoms were evident in the short term
(6 trials, pooled SMD −0.31; 95% CI −0.43 to −0.19,
p<0.00001) and depression remission was more likely
to be achieved with CC (5 trials, OR 1.77; 95% CI
1.28 to 2.44, p=0.0005). Likewise, a significant effect
was observed for anxiety symptoms (SMD −0.36) and
mental QOL (SMD 0.24). The timing of the
intervention was a source of between-group
heterogeneity for depression symptoms (between
groups p=0.04, I2=76.5%).
Conclusions: Collaborative depression care did not
lead to a sustained reduction in the primary MACE end
point. Small effects were observed for depression,
depression remission, anxiety and mental QOL.
Trials registration number: PROSPERO
CRD42014013653.
INTRODUCTION
Depression is widely reported to lead to an
adverse coronary heart disease (CHD)
prognosis,1 2 poorer quality of life (QOL)3 4
and high healthcare costs.5 Despite ongoing
efforts to better identify and treat depres-
sion,6 prior psychological and pharmaco-
logical interventions designed especially for
the CHD population have reported markedly
lower effect sizes than has been observed
among other chronic diseases such as dia-
betes.7 8 Moreover, large trials such as the
landmark Enhancing Recovery in CHD
(ENRICHD) study9 did not lead to a signiﬁ-
cant reduction in major adverse cardiac
events (MACE), raising questions about the
design10 and acceptability11 of depression
interventions in the population with CHD.
Collaborative care (CC) is emerging as a
promising model of healthcare among popu-
lations with complex mental health needs12
and mental disorders comorbid with chronic
diseases including diabetes and CHD.13 14
CC is deﬁned by a multiprofessional
approach to patient care delivered by a
primary care physician (PCP) and at least
one other health professional, involving a
structured patient management plan and
interventions, scheduled patient follow-ups,
and enhanced interprofessional communica-
tion between the multiprofessional teams.13
Prior systematic reviews have not reported on
the efﬁcacy of CHD studies in particular,15 16
although mixed CHD and diabetes samples
Strengths and limitations of this study
▪ Systematic review of randomised controlled trials
and a priori defined primary and secondary
outcomes.
▪ Exhaustive literature search and additional
unpublished data provided by 5 of 6 trials.
▪ GRADE rating of strength of evidence as
moderate.
▪ Heterogeneity observed between studies.
▪ Few studies performed outside of the USA.
▪ Insufficient healthcare cost data.
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are commonplace.13 Several large prospective rando-
mised controlled trials (RCTs) of CC versus usual care
have been reported recently,17–19 making it feasible to
examine the efﬁcacy and early beneﬁts of CC, which
might in turn assist in the design of subsequent trials
and inform clinical practice. This systematic review
extends beyond previous studies by reporting the efﬁ-




This review conformed to the PRISMA guidelines21 and
a protocol has been published elsewhere.20 Electronic
databases were searched without language restrictions
until April 2014: the Cochrane Central Register of
Controlled Trials (CENTRAL) on The Cochrane
Library, MEDLINE, EMBASE, PsycINFO and CINAHL.
The search string exploded the topics CHD, depression
and RCT, as reported previously.20 Hand searching refer-
ence lists of articles selected for full text supplemented
electronic searches. The principal investigators of studies
were contacted to ascertain unpublished data and their
knowledge of any other CC trials not included in our
primary search. Additional data were provided for ﬁve
trials17 18 22–24 and no response was received from the
TrueBlue study authors.19
Inclusion criteria
Population: RCT studies were performed among adults
(18 years and older) with comorbid depression and
CHD. Depression was deﬁned as depression disorder or
clinical depression assessed according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM) or
International Classiﬁcation of Diseases (ICD) by a stan-
dardised interview (eg, Structured Clinical Interview,
Composite International Diagnostic Interview) or a vali-
dated self-reports or rating scales with speciﬁc cut-off
points for depression. Mixed samples (eg, heart failure,
arrhythmia, diabetes) were eligible if ≥50% of the
sample had a CHD diagnosis.
Intervention: CC intervention is deﬁned as a coordi-
nated model of care involving multidisciplinary health-
care providers, including: (1) at least one health
professional (eg, nurse, psychiatrist, psychologist) in add-
ition to the PCP; (2) a structured patient management
plan that delivers either a pharmacological or a non-
pharmacological depression intervention; (3) scheduled
patient follow-up and (4) enhanced interprofessional
communication between the multiprofessional team. CC
may include usual CHD care or blended
depression-CHD care.
Comparison: control group was deﬁned as either
(enhanced) usual care, wait-list control (WLS) group or
no further treatment for comorbid depression-CHD.
Outcomes: primary; all-cause and CHD-related mortal-
ity as well as MACE (eg, subsequent myocardial
infarction (MI), coronary revascularisation procedure,
incident heart failure (HF), stroke).
Secondary: secondary outcomes include depression,
anxiety and QOL (measured either dimensionally or cat-
egorically) following the intervention assessed by vali-
dated self-report questionnaires or standardised
interviews. In addition, we considered economic evalua-
tions of healthcare costs or resource utilisation including
cost-effectiveness (incremental cost-effectiveness ratio)
and cost-utility (quality-adjusted life years).
Study selection process, risk of bias and assessment
Two reviewers (PJT and HB) independently screened
abstracts and articles for eligibility. In the case of title/
abstract disagreements, the study was subjected to full-
text review and disagreements were resolved by discus-
sion. Two reviewers (PJT and HB) independently assessed
included studies using the Cochrane Collaboration’s tool
for assessing risk of bias.25 The tool covers sequence gen-
eration, allocation concealment, selective outcome
reporting and other sources of bias. Adjudication of the
strength of evidence for each end point was made accord-
ing to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) criteria with
GRADE Proﬁler 3.6.1.26
Synthesis of data and summary measures
Standardised mean differences (SMD) for continuous
variables, risk ratios (RR) for MACE and ORs for dichot-
omous end points are reported with 95% CI. Data were
pooled together with random effects models using the
inverse-variance method.25 27 To evaluate the presence
of publication bias, the funnel plot was inspected. All
analyses were performed with RevMan V.5.3.
RESULTS
The search yielded 1755 citations from which 46 articles
were reviewed in detail, and 16 papers were retained
which reported on 6 RCTs (ﬁgure 1). Five CC trials per-
formed with diabetes and CHD or mixed chronic
disease populations were excluded as they did not meet
the threshold of more than 50% of patients with
CHD.13 28–31 Two trials were close to meeting the deﬁn-
ition of CC for depression comorbid with CHD, but
were excluded. The Identifying Depression as a
Comorbid Condition (IDACC)32 study was excluded as
the intervention did not initiate pharmacological or
non-pharmacological depression treatment and did not
involve structured follow-up of participants to augment
treatment if necessary. The UPBEAT-UK study33 was
excluded as the intervention was a case-management
intervention and did not incorporate other healthcare
professionals such as the PCP.
The 6 RCTs that met the inclusion criteria comprised
a total of 1284 patients with comorbid depression and
CHD: 655 participants randomised to CC and 629 parti-
cipants randomised to a control group. A description of
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the included trials is shown in table 1. The median pro-
portion of participants with CHD in the trials was
78.9%, suggesting a high representative sampling of the
chronic disease understudy. The median sample size was
179 participants per study with a median of 47.6%
female participants. Four trials recruited participants
from multiple sites11 34–36 and two trials were performed
at a single centre.17 37 Five trials were from the
USA17 18 22–24 and one trial was performed in
Australia.19 The comparison group was usual care or
enhanced usual care in ﬁve studies consisting of inform-
ing participants’ PCP17 18 22–24 and one trial used a
WLC group.36
Depression screening questionnaires varied only min-
imally. Depression was assessed with the Patient Health
Questionnaire (PHQ) to determine study eligibility in
four trials.17 19 23 24 Speciﬁcally, three trials used a
two-step screening approach with the PHQ-2 and a
PHQ-9 for participants with an initial positive depression
response on the PHQ-2.17 35 37 These trials used a moder-
ate depression threshold consisting of PHQ-9 total scores
≥10.17 35 37 The TrueBlue study36 included patients with
mild depression symptoms consisting of PHQ-9 scores
≥5. In the Coronary Psychosocial Evaluation Studies
(COPES) and Comparison of Depression Interventions
after Acute Coronary Syndrome (CODIACS) trials, the
Beck Depression Inventory (BDI) was used for screening
and trial eligibility.11 34 The clinical cut-off was set at ≥10
on at least two different screening occasions in COPES.11
In CODIACS,34 the clinical cut-off was set at BDI ≥10 on
at least two different screening occasions or BDI ≥15 on
one occasion. Five of the trials utilising either the
PHQ-917 36 37 or BDI11 34 to determine trial eligibility also
used the same measure for depression symptom response
at the conclusion of the trial. The Bypassing the Blues
trial employed the Hamilton Rating Scale for
Depression24 for depression symptom clinical response.
CC was managed by an allied health team in two
trials,11 34 by nurses in two studies35 36 and by social
workers in two studies.17 37 The CC intervention dur-
ation ranged from 3 to 12 months and the median dur-
ation was 6 months. The psychotherapy component of
the CC package consisted of problem-solving therapy in
two studies,11 34 telephone-delivered manualised CBT in
one study,37 referral to community mental health ser-
vices in two studies,35 36 and was mixed in another
study.17 The pharmacological component of the trials
varied. In Bypassing the Blues,35 depression pharmaco-
therapy consisted of citalopram, serotonin norepineph-
rine reuptake inhibitor (SNRI) or bupropion. In
Figure 1 Flow chart of article
selection (CC, collaborative care;
CHD, coronary heart disease;
RCT, randomised controlled trial).
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of CC vs UC
(% females
in total
sample) Depression assessment CC intervention Control group
Bypassing the
Blues, Rollman




CABG (100%) 150 CC vs
152 UC (41.4)
PHQ-2 positive screen as
an inpatient and PHQ-9
score ≥10 2 weeks
post-CABG, PRIME-MD for
mood disorders
Structured telephone follow-up, patient
preferences for depression care,
psychoeducation, bibliotherapy,
promoting adherence and initiation or
adjustment of antidepressant
pharmacotherapy provided by PCP
(citalopram, SNRI or bupropion);
referral to a community MHS; a













UA, MI (100%) 73 CC vs 77
UC (42.0)
BDI-I score ≥10 on 2
screening occasions or
≥15 on 1 occasion 2–
6 months after
hospitalisation
Initial patient preference for
problem-solving therapy and/or
pharmacotherapy (sertraline,
citalopram, bupropion), or neither; then
a stepped-care approach every
6–8 weeks, structured follow-up initially
every week with PST or 1–2 and
3–5 weeks to titrate doses with
pharmacotherapy; study team included













UA, MI (100%) 80 CC vs 77
UC (53.5)
BDI-I score ≥10 on 2
screening occasions
1 week and 3 months after
hospitalisation




mirtazapine), then a stepped-care
approach, repeated assessments and
augmentation if required at 8 week
intervals, structured follow-up initially
every week with PST or 1–2 and
3–5 weeks to titrate doses with
pharmacotherapy, study team included





care; PCP informed of
depression status
MOSAIC, Huffman
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of CC vs UC
(% females
in total
sample) Depression assessment CC intervention Control group
attacks as an inpatient and
PRIME-MD for depression,
GAD and PD
for pharmacotherapy (SSRI most
commonly citalopram, SNRI,
bupropion, mirtazapine and anxiety
treatment with SSRI or
benzodiazepine) or CBT (minimum 6
session CBT when allocated);
stepped-care; PCP informed of patient
preference; structured telephone call
and follow-up to monitor symptoms,
















screen and PHQ-9 score
≥10 as an inpatient
Social worker and psychiatrist
individualised depression treatment
recommendations based on history
and patient preference (SSRI or
psychotherapy); study team provided
the PCP or cardiologist with treatment
recommendations; verbal and written
recommendations to the inpatient
treatment team; depression education
for pleasant activities scheduling;















PHQ-9 score ≥5 as a
primary care patient
Scheduled visits to PN and PCP every
3 months over 12-months; referrals to






BDI-I, Beck Depression Inventory-I; CABG, coronary artery bypass graft; CBT; cognitive–behavioural therapy; CC, collaborative care; CHD, coronary heart disease; CODIACS, Comparison of
Depression Interventions after Acute Coronary Syndrome (Centralized, Stepped, Patient Preference-Based Treatment for Patients With Post-Acute Coronary Syndrome Depression); COPES,
Coronary Psychosocial Evaluation Studies; GAD, generalised anxiety disorder; HF, heart failure; MHS, mental health services; MI, myocardial infarction; MOSAIC, Management of Sadness and
Anxiety in Cardiology; PCP, primary care physician; PD, panic disorder; PHQ, Patient Health Questionnaire; PN, practice nurse; PRIME-MD, Primary Care Evaluation of Mental Disorders; PST,
problem-solving therapy; RCT, randomised controlled trial; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitors; SUCCEED, Screening Utilization and






























CODIACS,34 depression pharmacotherapy consisted of
sertraline, citalopram or bupropion. In COPES,11
pharmacotherapy consisted of sertraline, escitalopram,
venlafaxine, bupropion and mirtazipine. In
Management of Sadness and Anxiety in Cardiology
(MOSAIC),37 depression pharmacotherapy consisted of
selective serotonin reuptake inhibitor (SSRI, most com-
monly citalopram), SNRI, bupropion, mirtazapine and
anxiety treatment with SSRI or benzodiazepine. In
Screening Utilization and CC for More Effective and
Efﬁcient Treatment of Depression (SUCCEED),17
depression pharmacotherapy consisted of SSRI. No spe-
ciﬁc depression pharmacotherapy regimen was reported
in TrueBlue.36
Risk of bias
Risk of bias varied in the included primary trials (see
eSupplement 1). Missing trial characteristics were
common despite all studies having published a trial
protocol. In four trials, the allocation concealment was
unclear. Blinding to subjective end points was rated as
high in all studies. Selective reporting was noted in
three studies because of discrepancies in the study end
points reported in the protocol in comparison with the
primary trial results.
Primary outcome: major adverse cardiac events
Three trials reported MACE18 24 38 and pooling all data
irrespective of follow-up showed that CC did not reduce
MACE (RR=0.87; 95% CI 0.53 to 1.42, p=0.20, I2=39%).
CC was associated with signiﬁcant reduction in MACE
during the short to medium term (RR=0.54; 95% CI
0.31 to 0.95, p=0.03) that was not sustained in the long
term (>12 months follow-up) where only the COPES
trial39 reported MACE (RR 1.04; 95% CI 0.51 to 2.14,
p=0.91) (ﬁgure 2). There was no association with mor-
tality (5 trials, RR 1.38; 95% CI 0.53 to 3.58, p=0.51).
Secondary outcomes
Depression symptoms and remission
All six trials reported a change in self-reported depres-
sion symptoms by 6 months postintervention. CC was
associated with a signiﬁcant reduction in depressive
symptoms (pooled SMD −0.31; 95% CI −0.43 to −0.19,
p<0.00001: I2=13%) (ﬁgure 3). There was no depression
symptom data available in the medium or long term.
Four trials reported depression remission or clinically
signiﬁcant depression response and additional data were
provided by the MOSAIC trial.23 CC was signiﬁcantly
associated with depression remission (OR=1.77; 95% CI
1.28 to 2.44, p=0.0005: I2=23%) (ﬁgure 4). In the
medium term, only the COPES trial39 reported depres-
sion response based on the BDI ≤10 (OR 2.26; 95% CI
1.14 to 4.46, p=0.02). Since the COPES trial39 reported
similar depression remission results in the short to
medium term, pooling all depression remission data in
the ﬁve trials, irrespective of the time frame, indicated
similar results.
Other secondary outcomes
The forest plots for each of the secondary end points
are reported in eSupplements 2 to 5. Four trials
reported anxiety symptom change. It was found that CC
led to a small, but signiﬁcant reduction in anxiety symp-
toms in the short term (SMD −0.36; 95% CI −0.54 to
−0.17, p=0.0001: I2=25%). CC was also associated with a
signiﬁcant improvement in mental QOL in the short
term across ﬁve trials (SMD 0.23; 95% CI 0.08 to 0.38,
p=0.003: I2=27%), while effects for physical QOL were
non-signiﬁcant (SMD 0.11; 95% CI −0.03 to 0.25,
p=0.12: I2=13%). In terms of cost-effectiveness, there was
Figure 2 Forest plot showing the risk ratio for MACE postintervention in collaborative care studies versus usual care or waiting
list control (short and medium terms). MACE, major adverse cardiac events; IV, inverse variance; CODIACS, Comparison of
Depression Interventions after Acute Coronary Syndrome; COPES, Coronary Psychosocial Evaluation Studies.
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no signiﬁcant beneﬁt afforded by CC based on two trials
in the short term (SMD −0.09; 95% CI −0.32 to 0.13,
p=0.42: I2=0%). Medium-term results were reported by
Bypassing the Blues,40 which did not indicate signiﬁ-
cantly lower costs with CC (SMD 0.07; 95% CI −0.22 to
0.35, p=0.65).
Ancillary analyses
We performed ancillary analysis with each constituent of
the MACE end point encompassing acute coronary syn-
drome hospitalisations, coronary revascularisation, HF
and stroke. There was no signiﬁcant effect for CC to
reduce any of these more speciﬁc cardiovascular end
points (see eSupplements 6 to 9). Also, since ﬁve trials
differentiated between MACE and cardiac-cause hospital
readmissions, we performed an analysis according to the
latter outcome, which occurs more frequently. Analysis
of ﬁve trials showed no signiﬁcant reduction in cardiac-
cause hospital readmissions (RR=0.89; 95% CI 0.66 to
1.19, p=0.43: I2=35%) (see eSupplement 10).
Sensitivity analyses
For depression change, a sensitivity analysis was per-
formed excluding the trials comprised by patients with
diabetes without CHD19 and non-depressed patients
with CHD with anxiety.23 The sensitivity analysis revealed
a small increase in the effect size (pooled SMD −0.39;
95% CI −0.53 to −0.25, p<0.00001: I2=0%). We also eval-
uated the trials comprising patients with only CHD
(excluding other cardiac disorders) and assessed the
depression response. The trials were associated with
depression remission (OR=1.94; 95% CI 1.40 to 2.70,
p=<0.0001: I2=39%) and depression symptom reduction
(pooled SMD −0.43; 95% CI −0.59 to −0.27, p<0.00001:
I2=0%).
Figure 3 Forest plot showing depressive symptoms in collaborative care studies versus usual care or waiting list control (short
term). IV, inverse variance; SD; CODIACS, Comparison of Depression Interventions after Acute Coronary Syndrome; COPES,
Coronary Psychosocial Evaluation Studies; SUCCEED, Screening Utilization and CC for More Effective and Efficient Treatment
of Depression, MOSAIC, Management of Sadness and Anxiety in Cardiology.
Figure 4 Forest plot showing depression remission in collaborative care studies versus usual care or waiting list control (short
and medium terms). IV, inverse variance; CODIACS, Comparison of Depression Interventions after Acute Coronary Syndrome;
COPES, Coronary Psychosocial Evaluation Studies; SUCCEED, Screening Utilization and CC for More Effective and Efficient
Treatment of Depression, MOSAIC, Management of Sadness and Anxiety in Cardiology.
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The timing of depression onset41 and intervention11
after a cardiac hospitalisation has been raised by several
scholars as an important methodological consideration.
Thus, we stratiﬁed studies as providing CC immediately
on screening or as an inpatient17 36 37 versus those
which considered depression chronicity with a secondary
screener at a later stage and as an outpatient.11 34 35 It
was found that timing of depression intervention was a
source of between-group heterogeneity for depression
severity in six trials (between groups p=0.04, I2=76.5%)
(see eSupplement 11), but not for depression remission
(between groups p=0.50, I2=0% (see eSupplement 12).
When analysing the effect of CC in relation to com-
ponents of depression treatment, as described in our
protocol,20 it was found that CC was not associated
with a higher prescription rate of antidepressant medi-
cation (6 trials, OR=1.38; 95% CI 0.91 to 2.10, p=0.13,
I2=62%). There was no increase in the initiation of psy-
chological therapy with CC (6 trials, OR 2.01; 95% CI
0.85 to 4.76, p=0.11, I2=84%) (see eSupplements 13
and 14).
Publication bias and GRADE strength of recommendations
Testing for publication bias was inappropriate as fewer
than 10 RCTs were eligible. All of the primary and sec-
ondary outcomes were graded as being of moderate
strength according to the GRADE26 criteria (see
eSupplement 15).
DISCUSSION
This systematic review adds to the extant literature by
reporting the efﬁcacy and healthcare costs of CC inter-
ventions in comorbid depression and CHD populations.
It was found that CC was associated with a signiﬁcant
reduction in MACE in the short term (<6 months) that
was not sustained in the longer term. The absence of sig-
niﬁcant reduction in MACE in the longer term is com-
parable to other ﬁndings with pharmacological or
psychological interventions.8 42 The results pertaining to
the secondary depression end points indicated a small
albeit signiﬁcant reduction in depression symptoms with
CC, and depression remission was also more likely in the
short term. In addition, CC was associated with a signiﬁ-
cant reduction in anxiety symptoms and an improve-
ment in mental QOL. The ﬁndings did not suggest a
signiﬁcant beneﬁt for physical QOL or healthcare costs.
Taken together, the ﬁndings generally support previous
systematic reviews regarding more speciﬁc depression
treatments such as antidepressants or psychotherapy in
the population with CHD.8 42
The signiﬁcant reduction in MACE in the short term
is in contrast to a prior Cochrane review8 and other sys-
tematic reviews reporting on medical outcomes.43 44
However, the generalisation of our ﬁndings is limited as
only three trials reported the primary MACE end point
in the short term. Thus, it is most likely that there were
simply too few MACE reported, resulting in low statistical
power. This is further exempliﬁed by comparing the
cumulative sample in our analyses to the ENRICHD
study9 which randomised 2481 patients with MI to cogni-
tive–behavioural therapy supplemented with SSRIs
versus usual care. At the 29-month follow-up in the
ENRICHD trial, there was no difference in event free
survival from death or recurrent MI (75.8% intervention
vs 75.9% usual care).9 The longer term MACE ﬁndings
of our review align with the general consensus that
depression treatment does not lead to a clinically mean-
ingful impact on cardiovascular events in patients with
CHD.45–47 With regard to depression remission, short-
term results with CC were promising, indicating a higher
remission rate with CC. However, only the COPES trial39
reported medium-term follow-up data. With regard to
secondary end points of anxiety and mental QOL the
results here appear comparable to other systematic
reviews on psychological interventions.8
The limitations of the primary studies are that the pre-
dominant CC research has been performed in the
USA17 18 22–24 with only one Australian study included
here.19 Other CC trials that did not meet our CHD
threshold have been performed in the UK28 and the
Netherlands.48 Further trials with CHD populations may
assist in clarifying the extent to which CC can be readily
applied in other healthcare settings outside the USA. As
a consequence of low uptake of CC RCTs outside the
USA, the total number of RCTs retained for our
meta-analysis was low. Moreover, the infrequent report-
ing of MACE and mortality data in the original studies
limited our analyses to three trials. Another limitation
was that risk of bias assessment showed that some studies
were characterised by methodological limitations, espe-
cially a lack of blinding regarding intervention staff and
participants (which is not possible in CC interventions
when compared to usual care) and blinding of depres-
sion assessment (ie, only self-report instruments used).
Diversity in the design of the CC and control group
may have also led to heterogeneity between the studies.
In favour of a more comprehensive overview of the
topic, we included studies with diabetes19 and anxiety.23
As shown in sensitivity analyses, this might have underes-
timated the effect sizes when compared to cardiac-
depression populations only. Indeed, evidence for CC
appears to be more ﬁrmly established in the population
with diabetes,43 highlighting discrepancies between
depression intervention efﬁcacy in CHD.7 8 Given that
CC interventions consist of scheduled follow-up, it
cannot be ruled out that depression efﬁcacy was partly
attributable to the attention given to participants in the
treatment condition. Further RCTs using attention
control groups might also explicate whether treatment
effects are partly attributable to time spent with patients.
In conclusion, collaborative depression care in the
CHD population did not lead to a sustained reduction
in MACE. Small reductions in depressive symptoms were
evident for CC and intervention participants were more
likely to achieve depression remission. Small effect sizes
8 Tully PJ, Baumeister H. BMJ Open 2015;5:e009128. doi:10.1136/bmjopen-2015-009128
Open Access
group.bmj.com on September 19, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
for anxiety symptom reduction and improvement in
mental QOL were evident with CC. However, it remains
to be shown that collaborative depression care can lead
to sustained reductions in cardiovascular events and a
moderate depression response in the longer term. Scant
RCT data exist outside of the USA and the cost-
effectiveness has not been established at this time.
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